Leonie H E Leithold1, Nan Jiang1, Julia Post1, Tamar Ziehm1, Elena Schartmann1, Janine Kutzsche1, N Jon Shah2, Jörg Breitkreutz3, Karl-Josef Langen2,4, Antje Willuweit5, Dieter Willbold6,7. 1. Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich GmbH, 52425, Jülich, Germany. 2. Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich GmbH, 52425, Jülich, Germany. 3. Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. 4. Clinic for Nuclear Medicine, RWTH Aachen University, Aachen, Germany. 5. Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich GmbH, 52425, Jülich, Germany. a.willuweit@fz-juelich.de. 6. Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich GmbH, 52425, Jülich, Germany. d.willbold@fz-juelich.de. 7. Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. d.willbold@fz-juelich.de.
Abstract
PURPOSE: It has been shown that amyloid β (Aβ) oligomers play an important role in the pathology of Alzheimer's disease (AD). D3, a peptide consisting solely of D-enantiomeric amino acid residues, was developed to specifically eliminate Aβ oligomers and is therapeutically active in transgenic AD mice. D-peptides have several advantages over L-peptides, but little is known about their pharmacokinetic potential in vivo. Here, we analysed the pharmacokinetic properties of RD2, a rationally designed and potent D3 derivative. METHODS: The pharmacokinetic analysis was performed using (3)H-RD2 after administration via several routes in mice. The time dependent amount of radiolabelled RD2 was measured in plasma and several organ homogenates by liquid scintillation counting. Furthermore, binding to plasma proteins was estimated. RESULTS: RD2 penetrates into the brain, where it is thought to implement its therapeutic function. All administration routes result in a maximal brain concentration per dose (Cmax/D) of 0.06 (μg/g)/(mg/kg) with brain/plasma ratios ranging between 0.7 and 1.0. RD2 shows a small elimination constant and a long terminal half-life in plasma of more than 2 days. It also exhibits high bioavailability after i.p., s.c. or p.o. administration. CONCLUSIONS: These excellent pharmacokinetic properties confirm that RD2 is a very promising drug candidate for AD.
PURPOSE: It has been shown that amyloid β (Aβ) oligomers play an important role in the pathology of Alzheimer's disease (AD). D3, a peptide consisting solely of D-enantiomeric amino acid residues, was developed to specifically eliminate Aβ oligomers and is therapeutically active in transgenic ADmice. D-peptides have several advantages over L-peptides, but little is known about their pharmacokinetic potential in vivo. Here, we analysed the pharmacokinetic properties of RD2, a rationally designed and potent D3 derivative. METHODS: The pharmacokinetic analysis was performed using (3)H-RD2 after administration via several routes in mice. The time dependent amount of radiolabelled RD2 was measured in plasma and several organ homogenates by liquid scintillation counting. Furthermore, binding to plasma proteins was estimated. RESULTS:RD2 penetrates into the brain, where it is thought to implement its therapeutic function. All administration routes result in a maximal brain concentration per dose (Cmax/D) of 0.06 (μg/g)/(mg/kg) with brain/plasma ratios ranging between 0.7 and 1.0. RD2 shows a small elimination constant and a long terminal half-life in plasma of more than 2 days. It also exhibits high bioavailability after i.p., s.c. or p.o. administration. CONCLUSIONS: These excellent pharmacokinetic properties confirm that RD2 is a very promising drug candidate for AD.
Authors: O O Olubiyi; D Frenzel; D Bartnik; J M Glück; O Brener; L Nagel-Steger; S A Funke; D Willbold; B Strodel Journal: Curr Med Chem Date: 2014 Impact factor: 4.530
Authors: Nadine S Rösener; Lothar Gremer; Elke Reinartz; Anna König; Oleksandr Brener; Henrike Heise; Wolfgang Hoyer; Philipp Neudecker; Dieter Willbold Journal: J Biol Chem Date: 2018-08-21 Impact factor: 5.157
Authors: John R Horsley; Blagojce Jovcevski; Kate L Wegener; Jingxian Yu; Tara L Pukala; Andrew D Abell Journal: Biochem J Date: 2020-06-12 Impact factor: 3.857
Authors: Anne Elfgen; Michelle Hupert; Kevin Bochinsky; Markus Tusche; Estibaliz González de San Román Martin; Ian Gering; Silvia Sacchi; Loredano Pollegioni; Pitter F Huesgen; Rudolf Hartmann; Beatrix Santiago-Schübel; Janine Kutzsche; Dieter Willbold Journal: Sci Rep Date: 2019-04-05 Impact factor: 4.379